Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
Foghorn Therapeutics (NASDAQ:FHTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Analyst Expectations for Foghorn Therapeutics’s Future
Foghorn Therapeutics (NASDAQ:FHTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Crude Oil Down 1.5%; Philips Shares Jump After Q1 Results
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday.
The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16. The S&P 500, also fell, dropping, 0.01% to 4,132.91.
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
US Stocks Turn Lower; Nasdaq Dips 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday.
The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P 500, also fell, dropping, 0.32% to 4,120.38.
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
The FDA has put Foghorn Therapeutics Inc’s (NASDAQ:FHTX) study on partial hold after a patient had a severe heart-related safety event.…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers IN8bio (NASDAQ:INAB) shares increased by 69.5% to $1.78 during Monday’s pre-market session. The company’s market cap stands…
Reported Late Monday April 10, Foghorn Therapeutics To Present Preclinical Data From Its Selective CBP And EP300 Protein Degrader Programs And Preclinical Data For FHD-286, A Selective Inhibitor Of BRG1 And BRM At AACR April 14-19 2023
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that
Expert Ratings for Foghorn Therapeutics
Analysts have provided the following ratings for Foghorn Therapeutics (NASDAQ:FHTX) within the last quarter: Bullish Somewhat Bullish Indifferent…